Talzenna

Active Ingredient(s): Talazoparib Tosylate
FDA Approved: * October 16, 2018
Pharm Company: * PFIZER INC
Category: Cancer

Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.[2] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[3][4] It was approved in October 2018, in the United States and June 2019, in the European Union for germline BRCA-mutated, HER2-negative locally advanced or metasta... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Talzenna .25 mg Oral Capsule
NDC: 0069-0296
Labeler:
Pfizer Laboratories Div Pfizer Inc
Talzenna 1 mg Oral Capsule
NDC: 0069-1195
Labeler:
Pfizer Laboratories Div Pfizer Inc
Talzenna .5 mg Oral Capsule
NDC: 0069-1501
Labeler:
Pfizer Laboratories Div Pfizer Inc
Talzenna .75 mg Oral Capsule
NDC: 0069-1751
Labeler:
Pfizer Laboratories Div Pfizer Inc
Talzenna 1 mg Oral Capsule
NDC: 63539-295
Labeler:
U.S. Pharmaceuticals